{"id":18222,"date":"2026-09-22T10:18:26","date_gmt":"2026-09-22T10:18:26","guid":{"rendered":"https:\/\/veilles-affaires-sociales.fr\/?p=18222"},"modified":"2026-09-22T10:18:26","modified_gmt":"2026-09-22T10:18:26","slug":"evaluation-des-technologies-de-sante-nouvelle-possibilite-de-demander-une-consultation-scientifique-conjointe-titre-traduit-en-francais-par-lia","status":"publish","type":"post","link":"https:\/\/veilles-affaires-sociales.fr\/?p=18222","title":{"rendered":"\u00c9valuation des technologies de sant\u00e9 : nouvelle possibilit\u00e9 de demander une consultation scientifique conjointe\u00a0(titre traduit en fran\u00e7ais par l&rsquo;IA)"},"content":{"rendered":"<p>La Commission europ\u00e9enne ouvrira le 23 septembre 2026 la quatri\u00e8me p\u00e9riode de d\u00e9p\u00f4t de demandes de consultations scientifiques conjointes (Joint Scientific Consultations, JSC) dans le cadre de l\u2019\u00e9valuation des technologies de sant\u00e9 (HTA). Ces consultations permettent aux d\u00e9veloppeurs de technologies de sant\u00e9 de solliciter un avis sur la planification de leur technologie et sur la conduite des \u00e9tudes cliniques, afin de mieux pr\u00e9parer une future \u00e9valuation clinique conjointe (Joint Clinical Assessment).<\/p>\n<p>Les JSC sont accessibles pour des produits susceptibles de faire l\u2019objet d\u2019une \u00e9valuation clinique conjointe en application de l\u2019article 7, paragraphe 1, du r\u00e8glement HTA. La p\u00e9riode de d\u00e9p\u00f4t des demandes est fix\u00e9e du 23 septembre au 21 octobre 2026. Elle concerne les d\u00e9veloppeurs de m\u00e9dicaments ainsi que de dispositifs m\u00e9dicaux, pour ces derniers uniquement s\u2019ils sont class\u00e9s en classe IIb ou III, et les dispositifs m\u00e9dicaux de diagnostic in vitro class\u00e9s en classe D.<\/p>\n<p>Les demandes doivent \u00eatre soumises exclusivement durant cette fen\u00eatre sur la plateforme informatique HTA, au plus tard le 21 octobre 2026. Il est pr\u00e9cis\u00e9 que l\u2019obtention de l\u2019acc\u00e8s \u00e0 cette plateforme peut n\u00e9cessiter plusieurs jours, ce qui implique une anticipation des d\u00e9marches par les d\u00e9veloppeurs. Les cr\u00e9neaux de consultation propos\u00e9s correspondent \u00e0 des dates de remise des documents de cadrage (\u00ab briefing document \u00bb) et \u00e0 des semaines de r\u00e9union de discussion en 2027 : un premier couple 11 janvier \/ 12 avril 2027, un second 8 f\u00e9vrier \/ 10 mai 2027, et un troisi\u00e8me 15 mars \/ 7 juin 2027.<\/p>\n<p>L\u2019initiative est port\u00e9e par la Commission europ\u00e9enne et s\u2019inscrit dans la mise en \u0153uvre op\u00e9rationnelle du r\u00e8glement europ\u00e9en sur l\u2019\u00e9valuation des technologies de sant\u00e9. Elle pr\u00e9sente un int\u00e9r\u00eat de suivi pour les autorit\u00e9s nationales, notamment en mati\u00e8re de coordination europ\u00e9enne des \u00e9valuations cliniques et de pr\u00e9paration des industriels aux futures proc\u00e9dures conjointes. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l&rsquo;IA)\u00a0\u200b<a href=\"https:\/\/ec.europa.eu\/newsroom\/sante\/newsletter-archives\/79438\" target=\"_blank\" class=\"feedzy-rss-link-icon\">Lire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La Commission europ\u00e9enne ouvrira le 23 septembre 2026 la quatri\u00e8me p\u00e9riode de d\u00e9p\u00f4t de demandes de consultations scientifiques conjointes (Joint Scientific Consultations, JSC) dans le cadre de l\u2019\u00e9valuation des technologies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":17753,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[212,7,31],"tags":[258,227,226],"class_list":["post-18222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gestion-des-crises","category-medicaments-et-produits-de-sante","category-politiques-europeennes-sante-social-travail","tag-hera","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/18222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18222"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/18222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17753"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}